Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis
The Oncologist · 04.11.2024 · 29 (11) · e1425-e1434
DOI: 10.1093/oncolo/oyae134 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Oncologist, online erschienen am 28.06.2024. Verfasst von Shi-Jia Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taishan Scholars Program of Shandong Province, National Natural Science Foundation of China, Universities in Jinan.
Abstract (Originalsprache)
Backgrounds There is little evidence on the safety, efficacy, and survival benefit of restarting immune checkpoint inhibitors (ICI) in patients with cancer after discontinuation due to immune-related adverse events (irAEs) or progressive disease (PD). Here, we performed a meta-analysis to elucidate the possible benefits of ICI rechallenge in patients with cancer.
Methods
Systematic searches were conducted using PubMed, Embase, and Cochrane Library databases. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and incidence of irAEs were the outcomes of interest.
Results
Thirty-six studies involving 2026 patients were analyzed. ICI rechallenge was associated with a lower incidence of all-grade (OR, 0.05; 95%CI, 0.02-0.13, P < .05) and high-grade irAEs (OR, 0.37; 95%CI, 0.21-0.64, P < .05) when compared with initial ICI treatment. Though no significant difference was observed between rechallenge and initial treatment regarding ORR (OR, 0.69; 95%CI, 0.39-1.20, P = .29) and DCR (OR, 0.85; 95%CI, 0.51-1.40, P = 0.52), patients receiving rechallenge had improved PFS (HR, 0.56; 95%CI, 0.43-0.73, P < .05) and OS (HR, 0.55; 95%CI, 0.43-0.72, P < .05) than those who discontinued ICI therapy permanently. Subgroup analysis revealed that for patients who stopped initial ICI treatment because of irAEs, rechallenge showed similar safety and efficacy with initial treatment, while for patients who discontinued ICI treatment due to PD, rechallenge caused a significant increase in the incidence of high-grade irAEs (OR, 4.97; 95%CI, 1.98-12.5, P < .05) and a decrease in ORR (OR, 0.48; 95%CI, 0.24-0.95, P < .05).
Conclusion
ICI rechallenge is generally an active and feasible strategy that is associated with relative safety, similar efficacy, and improved survival outcomes. Rechallenge should be considered individually with circumspection, and randomized controlled trials are required to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China.
- Institute for Financial Studies, Shandong University, Jinan 250100, People's Republic of China.
- Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China.
ORCID-Profile: Tao Li
Förderung
- Taishan Scholars Program of Shandong Province
- National Natural Science Foundation of China
- Universities in Jinan
- Shandong Provincial Natural Science Foundation
Zitieren
APA
Liu, S. J., Yan, L. J., Wang, H. C., Ding, Z. N., Liu, H., Zhang, X., Pan, G. Q., Han, C. L., Tian, B. W., Yang, X. R., Tan, S. Y., Dong, Z. R., Wang, D. X., Yan, Y. C., & Li, T. (2024). Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis. The Oncologist, 29(11), e1425-e1434. https://doi.org/10.1093/oncolo/oyae134
Vancouver
Liu SJ, Yan LJ, Wang HC, Ding ZN, Liu H, Zhang X, et al. Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis. The Oncologist. 2024;29(11):e1425-e1434. doi:10.1093/oncolo/oyae134
BibTeX
@article{Liu2024,
author = {Liu, Shi-Jia and Yan, Lun-Jie and Wang, Han-Chao and Ding, Zi-Niu and Liu, Hui and Zhang, Xiao and Pan, Guo-Qiang and Han, Cheng-Long and Tian, Bao-Wen and Yang, Xiao-Rong and Tan, Si-Yu and Dong, Zhao-Ru and Wang, Dong-Xu and Yan, Yu-Chuan and Li, Tao},
title = {Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {11},
pages = {e1425--e1434},
doi = {10.1093/oncolo/oyae134}
}
EUVIMED